Krieger, Joshua Lev →

Science: The Unlikely Frontier for New Business Ideas

Iterative R&D might get products to market quickly, but innovation grounded in scientific research tends to be more valuable, says research by Joshua Lev Krieger and colleagues. Open for comment; 0 Comments.

Private and Social Returns to R&D: Drug Development and Demographics

Research and development (R&D) by pharmaceutical firms focuses disproportionately on medical conditions afflicting the elderly. The proportion of R&D spending targeting older age groups is increasing over time. Even though these investments in R&D prolong life expectancy and improve quality of life, they have little effect on measured productivity and output growth.

Find and Replace: R&D Investment Following the Erosion of Existing Products

This study sheds light on how product outcomes shape the direction of innovation and markets for technology. In the drug development industry in particular, negative product shocks appear to spur investment changes both within the directly affected firm and in competing firms in the same R&D markets.

In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?

Pharmaceutical companies are criticized for not producing more breakthrough drugs. But new research by Joshua Krieger and colleagues shows that, given a financial windfall, drug giants turn on the innovation. Open for comment; 0 Comments.

When a Competitor Abandons the Market, Should You Advance or Retreat?

Companies pay close attention when a competitor drops out of the market, according to new research by Joshua Lev Krieger. Too often, though, they come to the wrong conclusion. Open for comment; 0 Comments.

Developing Novel Drugs

This paper contributes to our understanding of how financing constraints affect the direction of innovation in drug development. The authors develop a new measure of drug novelty based on molecular characteristics, and explore the tradeoffs involved in decisions to develop more novel therapies. Open for comment; 0 Comments.

Trials and Terminations: Learning from Competitors' R&D Failures

When companies terminate R&D projects, it has ripple effects on the project selection decisions of rival firms and the broader competitive environment. Examining firm responses to others’ failures, this paper introduces a new model of R&D investment decisions, and empirically investigates when knowledge generated by rivals directly enters specific project investment decisions.